SCHEDULE 13G/A: BlackRock Discloses 8.3% Passive Stake in Twist Bioscience Corp
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.3% of Twist Bioscience Corp's common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 4,927,750 shares of Twist Bioscience Corp common stock.
- This represents 8.3% of the total outstanding common shares of Twist Bioscience Corp.
- The filing is an Amendment No. 6 to Schedule 13G, indicating previous filings by BlackRock regarding its stake.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Twist Bioscience Corp.
- BlackRock has sole voting power over 4,861,866 shares and sole dispositive power over 4,927,750 shares.
- Several BlackRock subsidiaries are identified as beneficially owning shares, with BlackRock Investment Management, LLC specifically noted as owning 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: The filing is a routine disclosure of a significant passive ownership stake by a major institutional investor, BlackRock, in Twist Bioscience Corp. While not providing operational details, the continued large holding by BlackRock can be interpreted as a vote of confidence in the company's long-term prospects, without indicating any immediate intent to influence control.
Positives
- A significant stake (8.3%) held by a major institutional investor like BlackRock can be interpreted as a vote of confidence in Twist Bioscience Corp's long-term prospects.
- The passive nature of the investment, as certified by BlackRock, suggests stability and no immediate intent to influence corporate control, which can be reassuring to other investors.
Negatives
- The document itself does not present any negative information regarding Twist Bioscience Corp's operational performance or financial outlook.
- The filing is a routine disclosure of ownership and does not inherently contain negative aspects related to the issuer.
Risks
- The document does not detail specific risks related to Twist Bioscience Corp's operations or financial health.
- As a passive investment, BlackRock's stake does not introduce new operational risks to the issuer.
- Potential future changes in BlackRock's ownership, though not indicated by this passive filing, could impact the stock price.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Twist Bioscience Corp, a company operating in the biotechnology and synthetic biology sectors. Large passive stakes by major asset managers like BlackRock are common across various industries, reflecting their broad market exposure and investment strategies. For the biotechnology sector, such investments can signal long-term confidence in the company's underlying technology and market potential, even if the investment is passive.
Comparison to Industry Standards
- Large institutional holdings, such as BlackRock's 8.3% stake in Twist Bioscience Corp, are a standard feature of publicly traded companies, particularly those with growth potential in sectors like biotechnology.
- While specific comparable companies or projects are not detailed in this filing, the presence of a major asset manager like BlackRock on the shareholder register is generally viewed as a positive indicator of a company's investability and market liquidity, aligning with typical institutional investment patterns in established and emerging growth companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | Not specified (previous appointees under revoked Power of Attorney) | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | Appointment of new attorneys-in-fact for regulatory filings, revoking a prior Power of Attorney. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Authorization Policy | BlackRock, Inc. updated its internal Power of Attorney, effective January 21, 2025, to designate specific individuals as attorneys-in-fact for executing regulatory filings. This action supersedes a previous Power of Attorney dated April 30, 2023. | 2025-01-21 | This is an internal administrative update for BlackRock's compliance procedures and does not directly affect the corporate governance structure or policies of Twist Bioscience Corp. |
Stakeholder Impact
- Shareholders: The disclosure of a large, passive institutional stake by BlackRock may provide a sense of stability and confidence, potentially attracting or retaining other institutional investors.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney, which was revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney issued by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting date for ownership percentage). |
| 2025-04-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
Twist Bioscience Corp, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Synthetic Biology, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.